Yating Liu

CONTACT

Lead Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Have signed an informed consent form before participating in the research.
•2. Male or female individuals aged 50 or above at the time of signing the informed consent form;
•3. Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
•4. At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).

•1. According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;
•2. The study eye has uncontrollable glaucoma;
•3. There is an active intraocular or periocular infection or inflammation in either eye;
•4. The non-study eye has severe visual function disorders;
•5. Within 90 days before baseline, the study eye had received anti-VEGF treatment;
•6. Within 90 days before baseline, the study eye had received anti-complement treatment;
•7. At any time before baseline, the study eye had received IBI302 treatment;
•8. Uncontrollable hypertension;
•9. Glycated hemoglobin (HbA1c) \> 10.0% within 28 days prior to screening;

Related studies

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

NCT06439576 · Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, and more

NCT05562947 · Neovascular Age-related Macular Degeneration, nAMD

NCT05904028 · Neovascular Age-related Macular Degeneration

NCT06213038 · Neovascular Age-related Macular Degeneration

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD